Has Paul Lui, MD received payments from drug or device companies?

Yes. Drug and device makers reported $206 in general payments to Paul Lui, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Paul Lui, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Paul Lui, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Paul Lui, MD

Urology · Loma Linda, CANPI 1396767653

Payments from drug & device makers

$206in general payments, 2019–2025

Across 11 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$54
Coloplast$45
Teleflex LLC$42
Convatec Inc.$27
Pelvital USA, Inc.$21
Otsuka America Pharmaceutical, Inc.$18

What the payments were for

Food & beverage$206100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	4	$54
Coloplast	2	$45
Teleflex LLC	2	$42
Convatec Inc.	1	$27
Pelvital USA, Inc.	1	$21
Otsuka America Pharmaceutical, Inc.	1	$18

How this compares

$206 in reported general payments places this provider in the 15th percentile of 1,324 urology providers in California.

See all urology providers in California →

Medicare billing

Part B allowed, 2024

$112,207

Medicare patients

413

Services billed

1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	53	$46,335
GemtesaVibegron	16	$14,814
Tamsulosin Hcl	740	$11,808
Finasteride	538	$5,755
Dutasteride	122	$4,904
Testosterone	20	$4,404
Methenamine Hippurate	33	$3,502
Potassium Citrate ErPotassium Citrate	23	$3,319
Tolterodine Tartrate ErTolterodine Tartrate	29	$2,688
Alfuzosin Hcl ErAlfuzosin Hcl	57	$1,247
Oxybutynin Chloride	35	$755
Bicalutamide	19	$677
Solifenacin Succinate	23	$659
Tadalafil	21	$524
Risperidone	32	$383

Paid to pharmacies, not to this prescriber.

Other urology in Loma Linda

Roger LiLoma Linda$2.3M
Brian HuLoma Linda$321K
Edward UchioOrange$21.1M
Stephen FreedlandWest Hollywood$16.7M
Alec KooTorrance$7.4M
Karim ChamieLos Angeles$4.3M
Ralph ClaymanOrange$3.9M
Siamak DaneshmandLos Angeles$3.5M
Arnold ChinLos Angeles$3.5M
John KowalczykLos Angeles$1.8M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →